News Reaction to MSD's UK exit as government tries to renew talks The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.
News Intercept pulls Ocaliva off the market in the US Alfasigma's $800m buyout of Intercept is starting to look like a poor bet as its only product, Ocaliva, is pulled from the market.
News J&J claims FDA okay for bladder cancer drug TAR-200 Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.
News Pharma says UK is 'tumbling down' rankings for investment The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.
News Fresh blow to UK life sciences as MSD abandons £1bn project In a blow to UK life science ambitions, MSD has scrapped a £1bn expansion of its operations in the country, saying it does not value innovation.
News ICER says GLP-1s 'still have serious affordability issues' Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.